Table 2.
Antibiotics susceptibilities grouped by study year
| Antibioticsa | Overall susceptibilities (%) (n = 968) | Susceptibilities by years (%) | ||
|---|---|---|---|---|
| 2002 (n = 495) | 2012 (n = 473) | P | ||
| Clindamycin | 174 (18.0) | 49 (9.9) | 125 (26.4) | < 0.001 |
| Ciprofloxacin | 432 (44.6) | 224 (45.3) | 208 (44.0) | 0.699 |
| Erythromycin | 79 (8.2) | 17 (3.4) | 62 (13.1) | < 0.001 |
| Linezolid | 968 (100) | 495 (100) | 473 (100) | – |
| Rifampicin | 841 (86.9) | 456 (92.1) | 385 (81.4) | < 0.001 |
| SXT | 557 (57.5) | 236 (47.7) | 321 (67.9) | < 0.001 |
| Tetracycline | 281 (29.0) | 70 (14.1) | 211 (44.6) | < 0.001 |
| Fosfomycin | 900 (93.0) | 478 (96.6) | 422 (89.2) | < 0.001 |
| Vancomycin | 968 (100) | 495 (100) | 473 (100) | – |
a Antibiotic abbreviation: SXT, trimethoprim/sulfamethoxazole